Bimekizumab Among Most Cost-Effective Treatments for PsA, Study Finds

Bimekizumab was found to be more cost-effective than most biologics and targeted synthetic disease-modifying antirheumatic drugs in a Swedish healthcare system-based model.

Related Keywords

Uppsala ,Uppsala Lan ,Sweden ,Swedish ,Valgerdur Sigurdardottir ,American College Of Rheumatology ,Arthritis Foundation ,Uppsala University ,Falun Hospital ,American College ,Psoriasis Area ,Severity Index ,Accessed October ,Psa ,Psoriatic Arthritis ,Bimekizumab ,Cost Effective ,Treatment ,Model ,Disease Modifying Antirheumatic Drugs ,Biologics ,Tnf Inhibitor ,